Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Rare Variants Affecting the Fanconi Anaemia DNA Repair Genes Associate with Increased Risk for AML

Kyaw Ze Ya Maung, BSc, Paul Leo, PhD, Anna L Brown, PhD, Mahmoud A Bassal, Bsc, BCompSc, Debora A. Casolari, PhD, Adam Ewing, B.A & PhD, Emma Duncan, PhD, Sarah C Bray, PhD, Evgeny Glazov, PhD, Luen Bik To, MBBS, FRACP, FRCPA, PhD, Russell Saal, MMSc, BSMedTech, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Paula Marlton, MBBS, FRACP, FRCPA, James X Gray, MD PhD, Thomas J Gonda, PhD, Richard D'Andrea, PhD

Blood (2016) 128 (22): 41.

https://doi.org/10.1182/blood.V128.22.41.41

Published: 2016

Journal Articles

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 1684.

https://doi.org/10.1182/blood.V128.22.1684.1684

Published: 2016

Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD

Blood (2016) 128 (22): 338.

https://doi.org/10.1182/blood.V128.22.338.338

Published: 2016

Journal Articles

Serum Levels Of CD178 (Soluble FasL) Predict Treatment Response and Survival In Chronic Lymphocytic Leukaemia (CLL)

Peter Mollee, Melinda Burgess, Nigel McMillan, Nicholas Saunders, Catherine Cheung, Michael Hallek, M.D. Ph.D., Devinder S Gill

Blood (2013) 122 (21): 2866.

https://doi.org/10.1182/blood.V122.21.2866.2866

Published: 2013

Journal Articles

Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients

Emma Taylor, Mark Jones, Matthew J Hourigan, David W Johnson, Devinder S Gill, Nicole Isbel, Carmel M Hawley, Paula Marlton, Maher K Gandhi, Scott B Campbell, Peter Mollee

Blood (2013) 122 (21): 1780.

https://doi.org/10.1182/blood.V122.21.1780.1780

Published: 2013

Journal Articles

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study

Eric Van Den Neste, MD, PhD, Christian Gisselbrecht, MD, Norbert Schmitz, Nicolas Mounier, MD, PhD, Devinder S Gill, David Linch FMedSci, Marek Trneny, MD, Ph.D.,, Noel Milpied, MD, PhD, John Radford, MD, Nicolas Ketterer, Ofer Shpilberg, MD, MPH, Ulrich Dührsen, MD, David Ma, MD, Josette Brière, MD, Catherine Thieblemont, MD, PhD, Gilles Andre Salles, MD, PhD, Craig H. Moskowitz, MD, Bertram Glass

Blood (2013) 122 (21): 764.

https://doi.org/10.1182/blood.V122.21.764.764

Published: 2013

Journal Articles

CD62L Expression Is Associated With Chronic Lymphocytic Leukemia (CLL) Cell Survival In Vitro and Represents a Novel Therapeutic Target In CLL

Melinda Burgess, Peter Mollee, Richa Singhania, Catherine Cheung, Lynne Chambers, Reynolds Brent, Louise Smith, Nicholas Saunders, Nigel McMillan, Devinder S Gill

Blood (2013) 122 (21): 4136.

https://doi.org/10.1182/blood.V122.21.4136.4136

Published: 2013

Journal Articles

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

Mathias Witzens-Harig, MD, Anthony D Ho, MD, Evelyn Kuhnt, Marek Trneny, MD, Michael Rieger, MD, Anders Österborg, MD, PhD, Ruth Pettengell, Robert Stevens, MD, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Jan Walewski, Markus Loeffler, Michael Pfreundschuh, MD

Blood (2012) 120 (21): 1612.

https://doi.org/10.1182/blood.V120.21.1612.1612

Published: 2012

Journal Articles

A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MB ChB, FRACP, FRCPA, David Simpson, FRACP, FRCPA, MBChB, Philip Campbell, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Marnie Collins, BCom, BSc(Hons), Paul Cortissos, Melanie Sulda, B.Sc, Ph.D., Giles Best, B.Sc., Ph.D., Bryone J Kuss, MBBS, PhD, FRCPA, FRACP

Blood (2012) 120 (21): 436.

https://doi.org/10.1182/blood.V120.21.436.436

Published: 2012

Journal Articles

ZAP-70 Expression Measured by Quantitative PCR (QPCR) As a Prognostic Marker in Chronic Lymphocytic Leukaemia (CLL)

Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Raymond H. Banh, MBBS, FRACP, FRCPA, Catherine Cheung, Russell Saal, Lynne Chambers, Tennille Pelly, Devinder S Gill, MD

Blood (2011) 118 (21): 4602.

https://doi.org/10.1182/blood.V118.21.4602.4602

Published: 2011

Journal Articles

A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,

Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Campbell Tiley, MBBS, FRACP, FRCPA, Ilona Cunningham, John Moore, Miles Prince, MD, FRACP, FRCPA, Paul Cannell, MBBS, FRCPA, FRACP, Steve Gibbons, FRCPA, FRACP, MB, CHB, Jill Tate, BSc, MSc, FFSc, Sanjoy Paul, PhD, MSc, Devinder S Gill, MD

Blood (2011) 118 (21): 3973.

https://doi.org/10.1182/blood.V118.21.3973.3973

Published: 2011

Journal Articles

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL,

Maher K Gandhi, PhD, FRACP, FRCPath, FRCP, Mark S. Hertzberg, MD, PhD, Erica Han, John F. Seymour, MD, PhD, Rodney Hicks, MB BS, MD, FRACP, Devinder S Gill, MD, Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Pauline Crooks, Kristen Radford, PhD, Frank Vari, Phd

Blood (2011) 118 (21): 3673.

https://doi.org/10.1182/blood.V118.21.3673.3673

Published: 2011

Journal Articles

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Linda Shen, FRCPA, Erica Han, Jamie P Nourse, PhD, Rod Lea, PhD, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Devinder S Gill, MD, Maher K Gandhi, PhD, FRACP, FRCPath, FRCP

Blood (2011) 118 (21): 1585.

https://doi.org/10.1182/blood.V118.21.1585.1585

Published: 2011

Journal Articles

Genome-Wide Analysis of Genetic Alterations In Acute Myeloid Leukaemia (Massively parallel, high-throughput, paired-end DNA sequencing and genotyping of an AML genome).

James X Gray, MD, PhD, Paul J Leo, PhD, Pamela Mukhopadhyay, PhD, Evgeny A Glazov, PhD, Patrick Danoy, PhD, Marina Donskoi, BSc, Anna Brown, PhD, Ian D. Lewis, MBBS, PhD, Richard J D'Andrea, PhD, Matthew A Brown, MBBS, MD, Paula Marlton, MBBS, Devinder S Gill, MD, Thomas Gonda, PhD

Blood (2010) 116 (21): 1690.

https://doi.org/10.1182/blood.V116.21.1690.1690

Published: 2010

Journal Articles

The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study.

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MD, William E. P. Renwick, MBBS, FRACP, Melanie L Sulda, BSc, Ph.D, O. Giles Best, BSc, PhD, Bryone J Kuss, PhD, FRCPA, FRACP, MBBS, John F Seymour, MD, FRACP

Blood (2010) 116 (21): 699.

https://doi.org/10.1182/blood.V116.21.699.699

Published: 2010

Journal Articles

Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Blood (2010) 116 (21): 111.

https://doi.org/10.1182/blood.V116.21.111.111

Published: 2010

NARROW

Rare Variants Affecting the Fanconi Anaemia DNA Repair Genes Associate with Increased Risk for AML

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Serum Levels Of CD178 (Soluble FasL) Predict Treatment Response and Survival In Chronic Lymphocytic Leukaemia (CLL)

Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study

CD62L Expression Is Associated With Chronic Lymphocytic Leukemia (CLL) Cell Survival In Vitro and Represents a Novel Therapeutic Target In CLL

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

ZAP-70 Expression Measured by Quantitative PCR (QPCR) As a Prognostic Marker in Chronic Lymphocytic Leukaemia (CLL)

A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL,

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Genome-Wide Analysis of Genetic Alterations In Acute Myeloid Leukaemia (Massively parallel, high-throughput, paired-end DNA sequencing and genotyping of an AML genome).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only